GCMS Signs Five-Year Extension of Blood Dialysis Fluid Supply Contract with Baxter

GCMS announced on March 8 that it has signed a long-term supply contract for blood dialysis fluid with Baxter Renal Division, the Korean subsidiary of Baxter.

Younghee Sagong, CEO of GC Green Cross MS (left), and Kwanghyuk Lim, CEO of Baxter Renal Division, are posing for a commemorative photo at the signing ceremony of the blood dialysis fluid supply contract.
[Photo by GC Green Cross MS]

The signing ceremony was attended by Younghee Sa, CEO of GCMS, Kwanghyuk Lim, CEO of Baxter Renal Division, and other officials from both companies. GCMS has supplied blood dialysis fluid to Baxter for five years from 2019 to last year, and with this new contract, the supply will continue until 2029.

GCMS completed its new blood dialysis fluid plant, Eumseong Plant 2, in 2019, making it the largest blood dialysis fluid facility in Korea. The company explained that it is capable of producing more than half of all blood dialysis fluid supplied domestically. The domestic blood dialysis fluid market is reportedly growing by about 7% annually, driven by an increase in dialysis patients due to population aging and the extended lifespan of existing patients with incurable conditions.

A GCMS official stated, "We hold approximately a 50% manufacturing share in the domestic blood dialysis fluid market," and added, "Through this long-term supply contract with Baxter, we expect stable sales and profits."

This content was produced with the assistance of AI translation services.